Pages that link to "Q67602665"
Jump to navigation
Jump to search
The following pages link to Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption (Q67602665):
Displaying 50 items.
- Role of osteocytes in multiple myeloma bone disease (Q26992195) (← links)
- The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis (Q27437809) (← links)
- Osteoblastogenesis and tumor growth in myeloma (Q33768466) (← links)
- A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease. (Q33843095) (← links)
- Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis (Q33854017) (← links)
- Myeloma bone disease (Q34326545) (← links)
- The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma (Q34340400) (← links)
- Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease (Q34720969) (← links)
- Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease (Q34806153) (← links)
- Induction of malignant plasma cell proliferation by eosinophils (Q34876626) (← links)
- Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model (Q35070415) (← links)
- Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment (Q35145704) (← links)
- Bone anabolic agents for the treatment of multiple myeloma (Q35603116) (← links)
- Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease (Q35631319) (← links)
- Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo (Q35642745) (← links)
- Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options (Q35678932) (← links)
- Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast (Q36086488) (← links)
- Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo (Q36478430) (← links)
- Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma (Q36732811) (← links)
- Bone disease in multiple myeloma (Q36737006) (← links)
- Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth (Q36742501) (← links)
- Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure (Q36902283) (← links)
- Treatment strategies for bone disease (Q36902828) (← links)
- Activation of the acquired immune response reduces coupled bone formation in response to a periodontal pathogen (Q37089072) (← links)
- Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. (Q37118787) (← links)
- The pathogenesis of the bone disease of multiple myeloma. (Q37136324) (← links)
- Targeting the bone microenvironment in multiple myeloma (Q37686353) (← links)
- Tumor-host cell interactions in the bone disease of myeloma (Q37771082) (← links)
- Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma (Q37853737) (← links)
- Supportive Therapy in Multiple Myeloma (Q37867574) (← links)
- Soluble molecules and bone metabolism in multiple myeloma: a review. (Q37998401) (← links)
- Myeloma and Bone Disease (Q38598342) (← links)
- Targeting the Bone Marrow Microenvironment. (Q38970585) (← links)
- Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. (Q39203918) (← links)
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma (Q39768627) (← links)
- A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer (Q40101765) (← links)
- Pathogenesis and management of bone lesions in multiple myeloma (Q41460446) (← links)
- Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation (Q42008119) (← links)
- Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease (Q42112624) (← links)
- Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. (Q44291805) (← links)
- Pathogenesis of myeloma bone disease (Q46224909) (← links)
- Decreased bone mineral density is common after autologous blood or marrow transplantation (Q47617769) (← links)
- Bone Disease in Multiple Myeloma (Q50888455) (← links)
- Animal Models of Bone Metastasis. (Q53489280) (← links)
- Myeloma bone disease: Pathophysiology and management. (Q55209965) (← links)
- Epigenetic-Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease (Q64088142) (← links)
- XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Runx2 Gene in Pre-osteoblasts to Overcome Differentiation Suppression. (Q64950655) (← links)
- Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma (Q71645285) (← links)
- Alendronate in the treatment of Paget's disease of bone (Q73157658) (← links)
- Bisphosphonates in multiple myeloma (Q74012662) (← links)